RhoVac is a pharmaceutical company. Today, the focus is on the development of vaccines for the treatment of metastatic cancer. Immunotherapy treatment is a significant part of the operations where the body's immune system is used to fight and eliminate cancer cell. The company's drug candidate is used in combination with surgery or radiation therapy. The company was established in 2007 and is based in Lund.
CEO
Chairman Of The Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Rutger Arnhult | 20,41 | 20,41 | 2021-06-30 |
| Nordic Cross Asset Management | 10,56 | 10,56 | 2021-06-30 |
| Anders Ljungqvist | 7,56 | 7,56 | 2021-06-30 |
| Avanza Pension | 4,28 | 4,28 | 2021-06-30 |
| Göran Källebo | 3,34 | 3,34 | 2021-06-30 |
| Nordnet Pensionsförsäkring | 2,43 | 2,43 | 2021-06-30 |
| Gunvald Berger | 1,86 | 1,86 | 2021-06-30 |
| Anders Bremer | 1,31 | 1,31 | 2021-06-30 |
| Nils Berntsson | 1,18 | 1,18 | 2021-06-30 |
| Lennart Sten | 1,16 | 1,16 | 2021-06-30 |
2021-08-27 Delårsrapport 2021-Q2
2021-11-12 Delårsrapport 2021-Q3
2022-02-11 Bokslutskommuniké 2021